Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

T cells must be activated before they can elicit damage to allografts, through interaction of their T cell receptor (TCR) with peptide-MHC complex and through accessory molecules. Signaling through accessory molecules or costimulatory molecules is a critical way for the immune system to fine tune T cell activation. An emerging therapeutic strategy is to target selective molecules involved in the process of T cell activation using biologic agents, which do not impact TCR signaling, thus only manipulating the T cells, which recognize alloantigen. Costimulatory receptors and their ligands are attractive targets for this strategy and could be used both to prevent acute graft rejection as well as for maintenance immunosuppression. Therapeutic agents targeting costimulatory molecules, notably belatacept, have made the progression from the bench, through nonhuman primate studies and into the clinic. This overview describes some of the most common costimulatory molecules, their role in T cell activation, and the development of reagents, which target these pathways and their efficacy in transplantation.

Original publication

DOI

10.1097/TP.0b013e31826d4672

Type

Journal article

Journal

Transplantation

Publication Date

27/02/2013

Volume

95

Pages

527 - 535

Keywords

Animals, Costimulatory and Inhibitory T-Cell Receptors, Drug Design, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Ligands, Lymphocyte Activation, Organ Transplantation, Signal Transduction, T-Lymphocytes, Transplantation Tolerance, Treatment Outcome